Michael Riggs

His research interests center on the immunobiology of bovine and human cryptosporidiosis, a common diarrheal disease of humans and livestock throughout the world caused by the parasitic protozoan parasites Cryptosporidium parvum and C. hominis. His laboratory's research has focused on characterizing immune responses to Cryptosporidium; development of recombinant vaccines, immunotherapeutics and new drug discovery for cryptosporidiosis; definition of the molecular pathogenesis of host cell recognition, attachment, and invasion by Cryptosporidium; animal model refinement for C. parvum and C. hominis; and improved methods for diagnosis. Since 1989, his Cryptosporidium research program has been supported by funding as Principal Investigator from the NIH, USDA, Bill and Melinda Gates and other private foundations and industry, and is currently supported for new drug discovery by NIH and private industry. Research discoveries during this period have led to 13 issued patents (8 U.S., 5 foreign) and two additional foreign patent applications pending for Cryptosporidium inventions, eight licensing agreements for patented intellectual property, and numerous refereed publications and scholarly book chapters.

Biosketch

https://arizona.app.box.com/file/868295441894

Selected Research Publications

http://www.ncbi.nlm.nih.gov/sites/myncbi/1p3Mrbqa5n7Qp/bibliography/48561276/public/?sort=date&direction=ascending